Pembrolizumab’s Potential in Treating Richter Transformation of CLL
June 4th 2024Yucai Wang, MD, PhD, discusses the rationale, methods, and design of a study evaluating the efficacy of pembrolizumab when given as both a monotherapy and in combination with B-cell receptor inhibitors for Richter transformation of CLL.
Watch
Emerging Treatment Options for Myelofibrosis
June 3rd 2024Dr. Bose discusses the potential role of other treatment modalities, such as ruxolitinib combination therapies or novel agents, in managing this patient's myelofibrosis and anemia, including the emerging treatment options that may be relevant to this case.
Watch
5-Year Data Supports Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
May 30th 2024Vikram Narayan, MD, discusses the significance of the 5-year overall survival and cystectomy-free survival rates of nadofaragene firadenovec-vncg in treating patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Watch
Personalized Cancer Treatment and Management With Oncolytic Viruses
May 29th 2024As part of its Speaking Out video series, Howard D. Edington, MD, explores how oncolytic viruses are revolutionizing personalized cancer therapy, the challenges of interpreting vast genetic data, and the exciting potential of these targeted therapies.
Watch